S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:CBDC - Apotheca Biosciences Stock Price, Forecast & News

$0.0001
-0.02 (-99.50 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range
$0.00
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.00
$0.31
Volume5,500 shs
Average Volume10,768 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulation, and delivery technologies for the healthcare and consumer care industry. The company is based in the United States.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBDC
CUSIPN/A
CIKN/A
WebN/A
Phone727-228-3994

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CBDC News and Ratings via Email

Sign-up to receive the latest news and ratings for CBDC and its competitors with MarketBeat's FREE daily newsletter.


Apotheca Biosciences (NASDAQ:CBDC) Frequently Asked Questions

What is Apotheca Biosciences' stock symbol?

Apotheca Biosciences trades on the NASDAQ under the ticker symbol "CBDC."

Has Apotheca Biosciences been receiving favorable news coverage?

News articles about CBDC stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apotheca Biosciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Apotheca Biosciences.

Who are some of Apotheca Biosciences' key competitors?

What other stocks do shareholders of Apotheca Biosciences own?

Who are Apotheca Biosciences' key executives?

Apotheca Biosciences' management team includes the folowing people:
  • Dr. P. C. Sundareswaran, Chairman, CEO & CFO
  • Ms. Deirdre Fernandes, COO & Director
  • Mr. John Verghese, CTO & Director (Age 58)
  • Mr. Craig Huffman, Legal Council
  • Karin Rohret, Sec.

How do I buy shares of Apotheca Biosciences?

Shares of CBDC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Apotheca Biosciences' stock price today?

One share of CBDC stock can currently be purchased for approximately $0.00.

How can I contact Apotheca Biosciences?

The company can be reached via phone at 727-228-3994.


MarketBeat Community Rating for Apotheca Biosciences (NASDAQ CBDC)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  24 (Thanks for Voting!)
Underperform Votes:  35 (Thanks for Voting!)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Apotheca Biosciences and other stocks. Vote "Outperform" if you believe CBDC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBDC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel